Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: Final results of a community-based observational Italian study

Stefania Eufemia Lutrino, Francesca Bergamo, Marta Schirripa, Gerardo Rosati, Antonio Avallone, Riccardo Giampieri, Stefano Cordio, Massimiliano Berretta, Fabiola Rojas Llimpe, Federica Edith Pisa, Sara Lonardi, Fotios Loupakis, Gianpiero Fasola, Giuseppe Aprile

Research output: Contribution to journalArticlepeer-review


Background: Although the efficacy and safety of combining first-line chemotherapy with bevacizumab in elderly patients with colorectal cancer (CRC) is supported by the results of a phase III trial, real-practice data are limited. Patients and Methods: Our multi-center, community-based observational study included 233 elderly patients with CRC (median age=73 years, range=70-84 years). Baseline comorbidities and geriatric evaluation were also analyzed. Pre-specified end-points of the study were safety, tolerability and outcome results. Results: The incidence of both chemotherapy-induced and specific bevacizumab-related toxicities was low, and not influenced by baseline concurrent morbidities. Median progression free survival (PFS) and median overall survival (OS) were 9.9 months and 23.6 months, respectively. Fifty-six percent of patients received second-line chemotherapy. Conclusion: The upfront treatment of older patients with CRC with chemotherapy and bevacizumab is safe and efficacious in a real-world setting. No un expected toxicities were reported. Multi-dimensional geriatric evaluation is under-used in clinical practice.

Original languageEnglish
Pages (from-to)2391-2399
Number of pages9
JournalAnticancer Research
Issue number4
Publication statusPublished - Apr 1 2015


  • Advanced colorectal cancer
  • Bevacizumab
  • Italian study
  • Older patients

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Bevacizumab and first-line chemotherapy fo<sup>r</sup> older patients with advanced colorectal cancer: Final results of a community-based observational Italian study'. Together they form a unique fingerprint.

Cite this